Drugs / BAY 3670549
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07625215 | Jul 2026 → May 2030 expected | atrial fibrillation | Bayer | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 3670549 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07625215 ↗ |
| Route | Intravenous | “intravenous (IV) treatment” NCT07625215 ↗ |